**Curriculum:**

\*Of note case-based discussions will often highlight learning objectives that are part of the current session but may also re-enforce learning objectives from other sessions.

| **Session/**  **Date** | # **of Cases**  **Assigned** | **Didactic** | **Tentative Speaker NCA** | **Learning Objectives: \*** |
| --- | --- | --- | --- | --- |
| Session 1:  Nov 4,  2020 | 1 | Diabetes Medications Part 1: Use of Older Diabetes Medications with Focus on Cardiovascular and Renal Data | Dr. Nicole Ehrhardt  Endocrinology UW | 1. Understand how to safely prescribe and use older diabetes medications such as DPP-4s. This will include information on physiology and mechanism of action, efficacy, safety, tolerability, managing side effects, and dosing and administration of individual drugs. 2. Assess the cardiac and renal benefits or lack of cardiac benefits in these older medications. |
| Session 2:  Nov 18  2020 | 1 | Diabetes Medications Part 2: Use of Newer Diabetes Medications with Focus on Cardiovascular and Renal Data | Dr. Nicole Ehrhardt  Endocrinology UW | 1. Understand how to safely prescribe and use “newer” diabetes medications such as GLP-1RA and SGLT-2i. This will include information on physiology and mechanism of action, efficacy, safety, tolerability, managing side effects, and dosing and administration of individual 2. Discuss oral diabetes medications that are uniquely positioned for primary care with emphasis on oral GLP-1RA and SGLT-2i class. 3. Understand when to use a GLP-1 RA versus a SGLT-2i, DPP-4, and/or insulin in different clinical situations (ASCVD, CKD, HF, obesity, hypoglycemia) |
| Session 3:  Dec 2,  2020 | 1 | Core Nutrition, Exercise Changes and Diabetes Medications for Weight Loss | Dr. Micheal Knight  IM/Obesity specialist | 1. Be able to optimize diabetes control with lifestyle and weight reduction techniques. 2. Understand which diabetes medications cause weight loss, weight gain or are weight neutral |
| Session 4:  Dec 16,  2020 | 1 | Initiating and Understanding Role/Place of Insulin in Type 2 Management | Dr. Barbra Onumah  Endo Medstar | 1. Increase comfort in indications for insulin initiation and insulin management in appropriate population |
| Session 5:  Jan 6,  2021 | 2 | Diabetes in the time of COVID | Dr. Irl Hirsch  UW Diabetes Institute | 1. Provide up-to-date evolving knowledge on benefit of diabetes medications in the time of COVID according to expert opinion in recent journal publications 2. Provide up-to-date evolving knowledge on ongoing clinical trials that pertain to diabetes and COVID |
| Session 6:  Jan 13, 2021 | 2 | Diabetes and Depression | Dr. Zeina Saliba  FM/Psychiatry | 1. Understand the link between depression and diabetes |
| Session 7:  Jan 27,  2021 | 2 | Diabetes Guideline Update | Dr. Gail Nunlee-Bland  Endocrinology, Howard | 1. Teach evidence-based recommendations for diabetes management using the newest diabetes guidelines for diabetes medications (ADA, AACE, ACC, KDIGO guidelines). |
| Session 8;  Feb 10,  2021 | 2 | Diabetes Partnership, Cultural Sensitivity and Advocacy for Equality in DM Management | Dr. Maria Belén Menucci  Endocrinology | 1. Understand clinician and patient related barriers to diabetes management (clinical inertia, compliance, shared-decision making) 2. Recognize the importance of patient engagement and “buy in” as part of the shared decision-making process in diabetes management. (HBA1c control, compliance, hypoglycemia, weight, side effects, CV and renal risk, technology and devices etc.) |
| Session 9:  Feb 24,  2021 | 2 | Motivational Tools for Diabetes and Remoting Monitoring: Glucose Meters and Continuous Glucose Monitoring Devices | Tamara Swigert, RN, CDE | 1. Discuss and encourage the appropriate use of different diabetes technology and devices to aid in DM management. Examples include: continuous glucose monitoring, glucometer use, smart insulin pen devices etc. |
| Session 10:  March 10,  2021 | 2 | Diabetes and Heart Disease | Dr. Richard Katz  Cardiology | 1. Increase awareness of the overlap of diabetes with disease states such as ASCVD, stroke, heart failure, CKD, and obesity |
| Session 11:  March,  24 2021 | 2 | Type 1 versus Type 2 Diabetes | Dr. Maria Belén Menucci,  Endocrinology | 1. Understand how to assess for type 1 or type 2 DM   2. Understand that insulin sparing agent maybe indicated early in type 1 diabetes |
| Session 12:  April 7,  2021 | 1 | "Beyond glycemic control”: Use of Diabetes Medications for Cardiovascular and Renal Indications | Dr. Gail Nunlee-Bland, Endocrinology, Howard | 1. Enhance knowledge on use of SGLT-2i and GLP-1RA for cardiac (ASCVD, HF) and renal (CKD, albuminuria) indications “beyond” glycemic management in appropriate populations. |
| Session 13:  April 21,  2021 | 2 | Retinopathy/Eye Disease: Primary Care “Pearls” | Dr. Marena Patronas  Ophthalmology | 1. Recognize red flags for need for specialty referral in order to minimize complications from diabetes especially in the time of COVID 2. Clinical pearls for eye disease |
| Session 14:  May 5,  2021 | 2 | Hypertension: Beyond the ACE and ARB in Diabetes and the time of COVID | Dr. Susie Lew  Nephrology | 1. Enhance HTN management 2. Provide up-to-date evolving knowledge on ongoing clinical trials that pertain to COVID, diabetes, and HTN |
| Session 15:  May 19,  2021 | 2 | Podiatry:  "Clinical Pearls" in Diabetes | Dr. Micheal Stempel Podiatry | 1. Recognize red flags for need for specialty referral in order to minimize complications from diabetes especially in the time of COVID 2. Clinical pearls for diabetes foot care |
| Session 16:  June 2, 2021 | 2 | Medications to Combat Insulin Resistance in Antipsychotics and HIV Medications | Dr. Nicole Ehrhardt  Endocrinology UW    Dr. Zeina Saliba  FM/Psychiatry | 1. Recognize medications that increase insulin resistance. Discuss early use of GLP-1RA + metformin at diagnosis to decrease insulin resistance and decrease incidence of the metabolic syndrome. |
| \*17: Targeted for Support Staff/RN | None | How to Support Diabetes Medication Prior Authorizations and Set-up Continuous Glucose Monitoring in your Clinic  (no CME credit) | Tamara Swigert, RN, CDE | 1. Ensure support staff understand how to aid in pre-authorizations for medications and CGM use and billing 2. Discuss how to read a diabetes formulary and give tips on navigation of the prior authorization process |

**\*Of note case-based discussions will often highlight learning objectives that are part of the current session but may also re-enforce learning objectives from other sessions.**